Tax withholding reduces Protara Therapeutics (TARA) officer’s share count

Rhea-AI Filing Summary

Protara Therapeutics, Inc. officer Jacqueline Zummo reported a tax-related share withholding transaction. On January 20, 2026, 6,578 shares of Protara common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards granted to her in January 2023 and January 2024.

After this withholding, Zummo directly beneficially owned 122,283 shares of Protara common stock. The filing characterizes the event as an automatic share withholding for taxes rather than an open-market sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zummo Jacqueline

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chf Scientific Operations Off

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		F		6,578(1)	D	$5.6	122,283	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 19, 2023 and January 19, 2024.

Remarks:

	/s/ Jacqueline Zummo	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Protara Therapeutics (TARA) report?

Protara Therapeutics reported that officer Jacqueline Zummo had 6,578 shares of common stock withheld on January 20, 2026 to cover taxes on vested RSUs.

What does the Form 4 transaction code "F" mean for TARA?

The code "F" indicates shares were withheld by the issuer to satisfy income tax obligations tied to the vesting of equity awards, not an open-market trade.

How many Protara Therapeutics shares does Jacqueline Zummo own after this transaction?

Following the tax withholding, Jacqueline Zummo directly beneficially owned 122,283 shares of Protara Therapeutics common stock.

Why were 6,578 Protara Therapeutics shares withheld from the officer?

The 6,578 shares were withheld to pay income taxes due upon the vesting of restricted stock unit awards granted to Zummo in January 2023 and January 2024.

Is the Protara Therapeutics Form 4 transaction an open-market sale?

No. The Form 4 describes an automatic share withholding for taxes, not a discretionary open-market sale of Protara Therapeutics shares.

What is Jacqueline Zummo’s role at Protara Therapeutics?

Jacqueline Zummo is an officer of Protara Therapeutics, serving as Chief Scientific Operations Officer as indicated in the filing.